Komori
Financial Results Presentation6090Human Metabolome Technologies,Inc.Information and Communications, Services and Others

Financial Results Presentation Materials for the Fiscal Year Ending June 2026

For the fiscal year ended June 2026, revenue and profit declined due to sluggish life sciences research support services and higher costs. The company also presented a new five-year medium-term management plan and announced a policy of targeting operating profit of ¥600 million, among other objectives, for the fiscal year ending June 2031.

Worth reading
57In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
-33
¥ millions (year-on-year change in revenue)
Wording
Conditional
How definitive the wording is.

Contents of this document

Financial Results PresentationFiscal year ended June 2026 (prior fiscal year)11 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales1,421 Millions of yen-2.3%
Operating profit209 Millions of yen-15.9%
Ordinary income206 Millions of yen-14.2%
Net income¥200 million -21.9%net income attributable to owners of the parent
Full-year earnings forecast
Net Sales
1,500 Millions of yen
Operating profit
220 Millions of yen
Ordinary income
220 Millions of yen
Net income
¥170 million net income attributable to owners of the parent
Earnings per share
¥31.37
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Company-wide profit plan not achieved
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Decline in large domestic academic projects-134 Millions of yen
  • Weak overseas operations-72 Millions of yen
  • Increase in sales of the health-claim prediction package
  • Increase in manufacturing costs due to capital investment and higher headcount
New initiatives
  • Launch of the Five-Year Medium-Term Management Plan TIAD6
  • Scheduled to launch self-pay medical testing using mass spectrometers from January 2027
  • Promote proposals and consulting using Hybrid AI in biomanufacturing support
  • Promote sales process reform, the use of AI and standardization
  • Implement a restricted stock plan for employees
Key KPIsA metric the company considers important as a management benchmark.
  • ROE10.8 %
    Year on year against the same period last year-2.8 percentage points
  • WACC3-4
    Year on year against the same period last yearDown
  • Cost of shareholders’ equity4-5
    Year on year against the same period last yearDown
  • PBR2 times
    Year on year against the same period last yearDown
  • PER17.2 times
    Year on year against the same period last yearDown
Segment results
  • Life Science research support services (LSS)
    Net Sales930 Millions of yen
    Year on year against the same period last year-18.6%
  • Functional materials development support services (FDS)
    Net Sales363 Millions of yen
    Year on year against the same period last year+16.6%
  • Bio-manufacturing support services (BMS)
    Net Sales127 Millions of yen
    Year on year against the same period last yearNewly included
Medium-term management plan targets
Plan nameFive-Year Medium-Term Management Plan TIAD6
Target fiscal yearFiscal year ending June 2031
Target value
  • Operating Profit600 Millions of yen
  • Operating Margin25 % or higher
  • ROE15 % or higher
  • Corporate Value
    DetailsDouble
Comparison with actual resultsFiscal year ended June 2026 results: operating profit of ¥209 million and ROE of 10.8%
Financial targets
Target
  • ROE15 % or higher
  • Operating Margin25 % or higher
Actual results
  • ROE10.8 %
Number of employees
Number of Employees65 People consolidated
Breakdown12 PhDs
Capital expenditures
500 Millions of yen secured as strategic investment funds for M&A, capital investment and other purposes
Annual Dividend
Annual dividend per share¥18
Acquisition of treasury shares
DetailsPromote flexible share repurchases. Consider further repurchases based on the results of ongoing share purchases and the interim results.
Contents of this document
ItemDetails
Document typeFinancial Results Presentation
Fiscal Period CoveredFiscal year ended June 2026 (prior fiscal year)
Net Sales1,421 Millions of yen (YoY -2.3%)
Operating profit209 Millions of yen (YoY -15.9%)
Ordinary income206 Millions of yen (YoY -14.2%)
Net income¥200 million (net income attributable to owners of the parent) (YoY -21.9%)
Full-year earnings forecastNet Sales 1,500 Millions of yen / Operating profit 220 Millions of yen / Ordinary income 220 Millions of yen / Net income ¥170 million (net income attributable to owners of the parent) / Earnings per share ¥31.37
Self-assessment against the planCompany-wide profit plan not achieved
Segment resultsSegment Life Science research support services (LSS) / Net Sales 930 Millions of yen / Year on year against the same period last year -18.6, Segment Functional materials development support services (FDS) / Net Sales 363 Millions of yen / Year on year against the same period last year 16.6, Segment Bio-manufacturing support services (BMS) / Net Sales 127 Millions of yen / Year on year against the same period last year Newly included
Breakdown of Factors Affecting the ChangeFactors Decline in large domestic academic projects / Amount -134 Millions of yen, Factors Weak overseas operations / Amount -72 Millions of yen, Factors Increase in sales of the health-claim prediction package / Amount Not disclosed, Factors Increase in manufacturing costs due to capital investment and higher headcount / Amount Not disclosed
Key KPIsIndicator name ROE / Value 10.8 % / Year on year against the same period last year -2.8 percentage points, Indicator name WACC / Value 3-4 / Year on year against the same period last year Down, Indicator name Cost of shareholders’ equity / Value 4-5 / Year on year against the same period last year Down, Indicator name PBR / Value 2 times / Year on year against the same period last year Down, Indicator name PER / Value 17.2 times / Year on year against the same period last year Down
Number of employeesNumber of Employees 65 People (consolidated) / Breakdown 12 PhDs / Change during the period Not disclosed
Medium-term management plan targetsPlan name Five-Year Medium-Term Management Plan TIAD6 / Target fiscal year Fiscal year ending June 2031 / Target value Item Operating Profit / Value 600 Millions of yen, Item Operating Margin / Value 25 % or higher, Item ROE / Value 15 % or higher, Item Corporate Value / Details Double / Comparison with actual results Fiscal year ended June 2026 results: operating profit of ¥209 million and ROE of 10.8%
Financial targetsTarget Item ROE / Value 15 % or higher, Item Operating Margin / Value 25 % or higher / Actual results Item ROE / Value 10.8 %
Annual DividendAnnual dividend per share ¥18 / Interim Not disclosed / End of period Not disclosed
Acquisition of treasury sharesDetails Promote flexible share repurchases. Consider further repurchases based on the results of ongoing share purchases and the interim results. / Amount Not disclosed / Number of Shares Not disclosed / Period Not disclosed
Capital expenditures500 Millions of yen (secured as strategic investment funds for M&A, capital investment and other purposes)
New initiativesLaunch of the Five-Year Medium-Term Management Plan TIAD6, Scheduled to launch self-pay medical testing using mass spectrometers from January 2027, Promote proposals and consulting using Hybrid AI in biomanufacturing support, Promote sales process reform, the use of AI and standardization, Implement a restricted stock plan for employees
Items this document does not state (13)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterProgress against full-year forecastUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookPayout ratioOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The main factors behind the deterioration in results were a decline in large domestic academic projects, weak overseas operations, and higher manufacturing costs resulting from capital investment and an increase in headcount. In functional materials development support, sales of the health-claim prediction package increased, while biomanufacturing support exceeded the initial sales target of ¥100 million.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results Presentation Materials for the Fiscal Year Ending June 2026 | Human Metabolome Technologies,Inc. (6090) timely disclosure | Komori